FluBlok, a Recombinant Hemagglutinin Influenza Vaccine

Overview

Journal Influenza Other Respir Viruses

Publisher Wiley

Specialty Microbiology

Date 2009 May 21

PMID 19453397

Citations 74

Authors

Manon M J Cox

Peter A Patriarca

John Treanor

Affiliations

Soon will be listed here.

Abstract

FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg-based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg-protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the 'Accelerated Approval' mechanism in the United States.

Citing Articles

Characterization of Endogenous Retroviral-like Particles Expressed from the Sf9 Cell Line.

Ma H, Bae E, Chin P, Khan A Viruses. 2025; 17(2).

PMID: 40006891 PMC: 11860259. DOI: 10.3390/v17020136.

Protein Expression Platforms and the Challenges of Viral Antigen Production.

Sookhoo J, Schiffman Z, Ambagala A, Kobasa D, Pardee K, Babiuk S Vaccines (Basel). 2025; 12(12.

PMID: 39772006 PMC: 11680109. DOI: 10.3390/vaccines12121344.

H9 Consensus Hemagglutinin Subunit Vaccine with Adjuvants Induces Robust Mucosal and Systemic Immune Responses in Mice by Intranasal Administration.

Lin L, Zhu S, Yang B, Zhang X, Wu H, Wu S Microorganisms. 2024; 12(11).

PMID: 39597683 PMC: 11596065. DOI: 10.3390/microorganisms12112294.

Multi-strain modeling of influenza vaccine effectiveness in older adults and its dependence on antigenic distance.

Urdy S, Hanke M, Toledo A, Ratto N, Jacob E, Peyronnet E Sci Rep. 2024; 14(1):27190.

PMID: 39516205 PMC: 11549341. DOI: 10.1038/s41598-024-72716-1.

Analysis of polyclonal and monoclonal antibody to the influenza virus nucleoprotein in different oligomeric states.

Myers M, Conlon M, Gallagher J, Woolfork D, Khorrami N, Park W bioRxiv. 2024; .

PMID: 39372734 PMC: 11451747. DOI: 10.1101/2024.09.12.612748.

References

Cox M, Karl Anderson D . Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influenza Other Respir Viruses. 2009; 1(1):35-40. PMC: 4634664. DOI: 10.1111/j.1750-2659.2006.00007.x. View

Treanor J, Schiff G, Hayden F, Brady R, Hay C, Meyer A . Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007; 297(14):1577-82. DOI: 10.1001/jama.297.14.1577. View

Powers D, McElhaney J, Florendo Jr O, Manning M, Upshaw C, Bentley D . Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J Infect Dis. 1997; 175(2):342-51. DOI: 10.1093/infdis/175.2.342. View

Treanor J, Wilkinson B, Masseoud F, Battaglia R, OBrien D, Wolff M . Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001; 19(13-14):1732-7. DOI: 10.1016/s0264-410x(00)00395-9. View

Goji N, Nolan C, Hill H, Wolff M, Noah D, Williams T . Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008; 198(5):635-41. DOI: 10.1086/590916. View

Treanor J, Betts R, Smith G, Anderson E, Hackett C, Wilkinson B . Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis. 1996; 173(6):1467-70. DOI: 10.1093/infdis/173.6.1467. View

Treanor J, Campbell J, Zangwill K, Rowe T, Wolff M . Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006; 354(13):1343-51. DOI: 10.1056/NEJMoa055778. View

Powers D, Smith G, Anderson E, Kennedy D, Hackett C, Wilkinson B . Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995; 171(6):1595-9. DOI: 10.1093/infdis/171.6.1595. View

Huber V, McCullers J . FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther. 2008; 10(1):75-85. View

10.

Wang K, Holtz K, Anderson K, Chubet R, Mahmoud W, Cox M . Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2005; 24(12):2176-85. PMC: 7115642. DOI: 10.1016/j.vaccine.2005.11.005. View

11.

Keitel W, Couch R, CATE T, Hess K, Baxter B, Quarles J . High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994; 32(10):2468-73. PMC: 264085. DOI: 10.1128/jcm.32.10.2468-2473.1994. View

12.

Bridges C, Fukuda K, Uyeki T, Cox N, Singleton J . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2002; 51(RR-3):1-31. View

13.

Treanor J, Schiff G, Couch R, Cate T, Brady R, Hay C . Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis. 2006; 193(9):1223-8. DOI: 10.1086/503050. View

14.

Keitel W, CATE T, Atmar R, TURNER C, Nino D, Dukes C . Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996; 3(5):507-10. PMC: 170397. DOI: 10.1128/cdli.3.5.507-510.1996. View

15.

Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster R . Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res. 1986; 4(3):251-61. DOI: 10.1016/0168-1702(86)90004-3. View

16.

Lakey D, Treanor J, Betts R, Smith G, Thompson J, Sannella E . Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis. 1996; 174(4):838-41. DOI: 10.1093/infdis/174.4.838. View

17.

Renfrey S, Watts A . Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine. 1994; 12(8):747-52. DOI: 10.1016/0264-410x(94)90227-5. View

18.

Safdar A, Rodriguez M, Fayad L, Rodriguez G, Pro B, Wang M . Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006; 194(10):1394-7. DOI: 10.1086/508493. View

19.

Kida H, Webster R, Yanagawa R . Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/seal/Massachusetts/1/80 (H7N7) influenza virus. Arch Virol. 1983; 76(2):91-9. DOI: 10.1007/BF01311693. View